Clinical application of radioimmunoimaging with 99mTc-BDI-1 in the diagnosis of bladder cancer.
OBJECTIVE
To evaluate the clinical application of radioimmunoimaging (RII) with 99mTc-BDI-1 in the diagnosis of bladder cancer.


METHODS
32 patients with bladder cancer and 5 with normal bladder were studied. RII was performed 1 hour after intravesical administration of 111-222 MBq 99mTc-BDI-1 followed by washing out and perfusing bladder with 50 ml PBS. The radioactivity ratio of target over background (CT/CB) was calculated.


RESULTS
The radiochemical purity of 99mTc-BDI-1 was greater than 95%. RII showed radioactive accumulation area for most of bladder cancers but no radio-active concentration for normal bladder. The sensitivity and specificity were 91.7% and 81.8% respectively with the assignment of the positive criterion of CT/CB > or = 1.40. There was no statistical difference in sensitivity between tumors with diameters > or = 1 cm (1.0-4.2 cm) and < 1 cm (0.2-0.8 cm). CT/CB was related to the pathological grade (G1-G3) of the tumor.


CONCLUSIONS
RII by intravesical administration provides a new noninvasive method for the diagnosis of bladder cancer in morphology and in nature of tumor with high sensitivity and specificity. It may be used for the early diagnosis of bladder cancer, follow-up after surgery, and diagnosis of in situ tumor.
Wang
R
R
Department of Nuclear Medicine, First Hospital, Beijing Medical University, Beijing 100034, China.
Zhang
C
C
Yu
L
L
Guo
Y
Y
D000283:Administration, Intravesical; D000911:Antibodies, Monoclonal; D006801:Humans; D016719:Radioimmunodetection; D012680:Sensitivity and Specificity; D013667:Technetium; D001749:Urinary Bladder Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology
D000911:Antibodies, Monoclonal; D013667:Technetium